Federal Register #DEA1721

DEA Notice: Application to Import Controlled Substances by AndersonBrecon, Inc. DBA PCI Pharma Services

This opportunity concerns the Drug Enforcement Administration's (DEA) notice of an application to import controlled substances: - Government Buyer: - U.S. Department of Justice, Drug Enforcement Administration (DEA) - OEM/Vendor: - AndersonBrecon, Inc. DBA PCI Pharma Services - Products/Controlled Substances Requested: - Derivatives of Cocaine (drug code 9041) for analytical and reference standard purposes - Intermediate of Lysergic acid diethylamide (drug code 7315) as a bulk Active Pharmaceutical Ingredient - Tetrahydrocannabinols (drug code 7370) as dosage units for clinical trials - Methadone (drug code 9250) as dosage units for clinical trials - Thebaine (drug code 9333) as dosage units for clinical trials - Unique/Notable Requirements: - Import authorization is strictly limited to the specified research, analytical, and clinical trial purposes - No import of FDA-approved or non-approved finished dosage forms for commercial sale is permitted - The DEA is soliciting comments, objections, and hearing requests from interested parties - OEM Highlight: - AndersonBrecon, Inc. DBA PCI Pharma Services is the only OEM/vendor mentioned

Description

AndersonBrecon, Inc. DBA PCI Pharma Services has applied to be registered as an importer of basic class(es) of controlled substance(s). The application includes importing derivatives of Cocaine for analytical and reference standard purposes, an intermediate of Lysergic acid diethylamide as bulk Active Pharmaceutical Ingredient, and other listed controlled substances as dosage units to support clinical trials. No other activities for these drug codes are authorized for this registration. Comments and objections to the application are invited, with a deadline of July 17, 2026, and interested parties may request a hearing by the same date.

View original listing